PRESS-RELEASE filed Nov 11, 2026 at 16:05 ET
Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate its investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi) in a clinical study for patients with squamous cell anal carcinoma (SCAC) who have progressed on first-line therapy. The study is expected to begin in Q1 2027 at a U.S. cancer center, with Coherus supplying LOQTORZI. This is a non-financial collaboration that provides drug supply and supports a focused clinical evaluation in an indication with no approved second-line therapy.